News >

Immunotherapy Efforts Forge Ahead in Stage III NSCLC

Jessica Hergert
Published: Monday, Nov 04, 2019

Gregory M. M. Videtic, MD, CM, FRCPC

Gregory M. M. Videtic, MD, CM, FRCPC

The shift in standard of care, based on results from the phase III PACIFIC trial, continue to underscore the role of immunotherapy for patients with stage III unresectable non–small cell lung cancer (NSCLC), said Gregory M. M. Videtic, MD, CM, FRCPC.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x